Clinical Trials Logo

Malignant Hyperthermia clinical trials

View clinical trials related to Malignant Hyperthermia.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT02561598 Withdrawn - Clinical trials for Malignant Hyperthermia

A Case Control Study of Patients With Diagnosis of Malignant Hyperthermia

Start date: May 2023
Phase:
Study type: Observational

The purpose of the study is to develop methods to identify predictors of Malignant Hyperthermia.

NCT ID: NCT01624558 Withdrawn - Clinical trials for Malignant Hyperthermia

Effectiveness of Carbon Filters to Reduce the Anesthetic Gas Concentration in an Anesthetized Patient

Start date: July 2012
Phase: N/A
Study type: Interventional

Malignant hyperthermia is a potentially fatal inherited disorder triggered by exposure to volatile anesthetic gases, most commonly recognized in children during anesthesia. Carbon filters have been used to scavenge various gases. A new carbon filter (Vapor Clean, Dynasthetics, LLC, Salt Lake City, Utah) with a 510(k) clearance specifically for scavenging anesthetic gases is being marketed, though the filter itself has never been studied in vivo. Bench studies conducted by the manufacturer of the product demonstrate it is extremely effective in reducing the volatile gas output from an anesthesia machine within 2 minutes. This pilot study will measure the effect on volatile gas concentration in non-malignant hyperthermia susceptible patients. Twelve (12) patients will undergo standard anesthetic induction using inhalational anesthetic (Sevoflurane®) and maintained on 3% for 30 minutes to attain steady state concentrations.1 At that time, a total intravenous anesthetic technique will be started and maintained throughout the case. Simultaneously a Vapor Clean filterset will be placed in the breathing circuit (inspiratory and expiratory limbs). Volatile gas concentration will be measured and recorded. This research will determine the feasibility of using this carbon filter to quickly reduce the breathing circuit gas concentration of volatile anesthetic in the clinical setting. This is fundamental in establishing this as a key life saving measure in eliminating the stimulus in a malignant hyperthermia event.